- ►annals.org BMR Spiegel, L Targownik, GS Dulai, IM … - Annals of internal medicine, 2003 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
Background: Rofecoxib and celecoxib (coxibs) effectively treat chronic ... Cited by 103 - Related articles - BL Direct - All 12 versions
A Maetzel, M Krahn, G Naglie - Arthritis & Rheumatism, 2003 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 52 - Related articles - BL Direct - All 3 versions
BMR Spiegel, CF Chiou, JJ Ofman - Arthritis and Rheumatism-Arthritis Care and Research, 2005 - researchcore.org Objective. To appraise the cost-effectiveness of competing therapeutic
strategies in patient cohorts eligible for aspirin prophylaxis with varying
degrees of gastrointestinal (GI) and cardiovascular risk. Methods. Cost- ... Cited by 53 - Related articles - View as HTML - All 8 versions
HB El-Serag, DY Graham, P Richardson, JM … - Archives of Internal Medicine, 2002 - Am Med Assoc Methods A decision tree model was used for patients requiring long-term
treatment with NSAIDs to compare conventional NSAID therapy alone with 7 other
treatment strategies to reduce the risk of NSAID-related clinical UGI ... Cited by 37 - Related articles - BL Direct - All 5 versions
JM Pellissier, WL Straus, DJ Watson, SX … - Clinical therapeutics, 2001 - Elsevier Results: Under base-case conditions, the expected cost savings in GI problems
and comedications averted with rofecoxib versus NSAIDs was $0.81 per day,
representing an 85% offset of the difference in drug price. For rofecoxib ... Cited by 40 - Related articles - BL Direct - All 5 versions
- ►adisonline.com [PDF] RA Zabinski, TA Burke, J Johnson, F Lavoie, C … - Pharmacoeconomics, 2001 - ingentaconnect.com 1 Pharmacia Corporation, Global Health Outcomes, Skokie, Illinois, USA 2
University of Alberta College of Pharmacy, Alberta, Canada 3 Pfizer Outcomes
Research, Montreal, Canada 4 Pfizer Outcomes Research, New York, NY, USA 5 ... Cited by 47 - Related articles - BL Direct - All 5 versions
AM Fendrick, RR Bandekar, ME Chernew, JM … - Arthritis & Rheumatism, 2002 - interscience.wiley.com To mimic clinical practice, a symptom-driven decision analytic model was
constructed to compare 2 treatment strategies for long-term users of NSAIDs over
a 1-year period: Strategy 1 - generic NSAID used initially, and safer, more ... Cited by 36 - Related articles - BL Direct - All 3 versions
[CITATION] Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor
- ►mcmaster.ca [PDF] JK Marshall, JM Pellissier, CL Attard, SX … - Pharmacoeconomics, 2001 - ingentaconnect.com 1 Division of Gastroenterology, Department of Medicine, McMaster University,
Hamilton, Ontario, Canada 2 Merck Research Laboratories, Blue Bell,
Pennsylvania, USA 3 Innovus Research Inc., Burlington, Ontario, Canada 4 ... Cited by 48 - Related articles - BL Direct - All 7 versions
PP Geusens, K Truitt, P Sfikakis, PL Zhao, L … - Scandinavian journal of rheumatology, 2002 - informahealthcare.com Objective: To evaluate the eYcacy and tolerability of rofecoxib 25mg and 50mg
once daily versus placebo and naproxen 500mg twice daily in patients with RA.
Methods: Eligible patients were randomized (double-blind) to placebo (n ... Cited by 35 - Related articles - BL Direct - All 9 versions
